Navigation Links
Defensins neutralize anthrax toxin

Researchers at the University of Pennsylvania School of Medicine have identified a link between a critical cancer pathway and an Epstein-Barr Virus (EBV) protein known to be expressed in a number of EBV-associated cancers. Their findings demonstrate a new mechanism by which EBV transforms human B cells from the immune system into cancerous cells, which can lead to development of B-cell lymphomas.

Erle S. Robertson, PhD, Associate Professor of Microbiology and Director of Tumor Virology, with Penn's Abramson Cancer Center and MD/PhD student Jason Knight, published their results in the early March issue of Molecular and Cellular Biology.

Using human cell cultures infected with the Epstein-Barr virus, the investigators found that a specific viral protein targets a molecule that normally regulates the cell-cycle progression, or duplication process, of resting B cells. In the presence of this viral protein ?called EBNA3C (for EBV nuclear antigen) ?the cell cycle of the usually quiescent human B cells gets a jump start, which ultimately initiates uncontrolled growth.

EBV, a member of the herpesvirus family and one of the most common human viruses, plays a role in cancers such as lymphoproliferative diseases in transplant or AIDS patients, Burkitt's lymphoma, Hodgkin's lymphoma, and nasopharyngeal carcinoma, and also causes the well-known disease, infectious mononucleosis. As many as 95 percent of adults 20 years and older have been infected with EBV, but show no symptoms.

"Viruses that are associated with cancers typically target the cell cycle to gain control," says Robertson. "However, this is the first time that laboratory research into how EBV drives the cancer process has directly identified a critical component of the cell cycle for control. Now we can develop targeted therapeutics to disrupt the function of this viral protein." The researchers surmise that the first use of future therapies from these studies will be in lymphoprolifera tive disease in transplant and immunocompromised patients because this is a clear case of EBV-driven B-cell lymphoma.

The use of peptides to block the interaction between this essential EBV protein and the specific pathway in human B cells is currently underway. Initial studies show that the growth of EBV-associated cancer cells can be inhibited in tissue-culture assays. The investigators are actively pursuing this line of investigation for developing potential therapies.


'"/>

Source:


Related biology news :

1. Defensins Ward Off HIV In Two Ways
2. Bleach found to neutralize mold allergens
3. Scientists seek answers on what activates deadly anthrax spores
4. Antibodies from plants protect against anthrax
5. Critical step traced in anthrax infection
6. US Army plans to bulk-buy anthrax
7. New antibody shows promise as cure for anthrax
8. Effective, safe anthrax vaccine can be grown in tobacco plants
9. UCSD study finds anthrax toxins also harmful to fruit flies
10. Driver of anthrax toxicity could lead to late-stage therapy
11. Scientists design potent anthrax toxin inhibitor
Post Your Comments:
*Name:
*Comment:
*Email:


(Date:4/18/2017)... 2017  Socionext Inc., a global expert in SoC-based imaging and ... the M820, which features the company,s hybrid codec technology. A demonstration ... Probe, Inc., will be showcased during the upcoming Medtec Japan at ... the Las Vegas Convention Center April 24-27. ... Click here for an ...
(Date:4/13/2017)... , April 13, 2017 According to a ... Identity Authentication, Identity Analytics, Identity Administration, and Authorization), Service, Authentication Type, Deployment ... the IAM Market is expected to grow from USD 14.30 Billion in ... Rate (CAGR) of 17.3%. ... MarketsandMarkets Logo ...
(Date:4/11/2017)... BROOKLYN, N.Y. , April 11, 2017 /PRNewswire-USNewswire/ ... identical fingerprints, but researchers at the New York ... University College of Engineering have found that partial ... fingerprint-based security systems used in mobile phones and ... previously thought. The vulnerability lies in ...
Breaking Biology News(10 mins):
(Date:5/21/2017)... ... May 20, 2017 , ... CNSDose is a ... and error process by finding the right antidepressant faster. CNSDose speeds recovery ... relationship through a personalized approach to treatment. , A peer-reviewed and ...
(Date:5/18/2017)... , ... May 18, 2017 , ... ... on April 28, 2017 at the Prince Of Wales Private Hospital. The procedure ... at level C6-C7. The patient failed conservative treatments prior to undergoing surgery. , ...
(Date:5/18/2017)... ROCHELLE, VIRGINIA (PRWEB) , ... May 17, 2017 , ... ... senior business executive and former CEO of Eurofins Advantar Laboratories and President of Pharmaceutical ... In addition to his position at Eurofins and Cardinal Health, he was former Chief ...
(Date:5/18/2017)... ... 17, 2017 , ... USDM Life Sciences , the ... sciences and healthcare industries, is honored that Jay Crowley was selected ... Brussels, Belgium. , Crowley played a crucial role in the development of the ...
Breaking Biology Technology: